Reader TTS

ABSTRACT Hepatitis B virus (HBV) causes chronic hepatitis in humans, and current antiviral therapies rarely treat viral infections. To improve the treatment efficacy, novel therapeutic

agents, especially those with different mechanisms of action, need to be developed for use in combination with the current antivirals. Here, we isolated new anti-HBV compounds, named

catenulopyrizomicins A–C, from the fermentation broth of rare actinomycete _Catenuloplanes_ sp. MM782L-181F7. Structural analysis revealed that these compounds contained a structure that is

composed of thiazolyl pyridine moiety. The catenulopyrizomicins reduced the amount of intracellular viral DNA in HepG2.2.15 cells with EC50 values ranging from 1.94 to 2.63 µM with small but

notable selectivity. Mechanistic studies indicated that catenulopyrizomicin promotes the release of immature virion particles that fail to be enveloped through alterations in membrane

permeability. Access through your institution Buy or subscribe This is a preview of subscription content, access via your institution ACCESS OPTIONS Access through your institution Subscribe

to this journal Receive 12 print issues and online access $259.00 per year only $21.58 per issue Learn more Buy this article * Purchase on SpringerLink * Instant access to full article PDF

Buy now Prices may be subject to local taxes which are calculated during checkout ADDITIONAL ACCESS OPTIONS: * Log in * Learn about institutional subscriptions * Read our FAQs * Contact

customer support SIMILAR CONTENT BEING VIEWED BY OTHERS EVALUATION OF A-AZEPANO-TRITERPENOIDS AND RELATED DERIVATIVES AS ANTIMICROBIAL AND ANTIVIRAL AGENTS Article 12 July 2021 AN

ANTI-INFLUENZA A VIRUS MICROBIAL METABOLITE ACTS BY DEGRADING VIRAL ENDONUCLEASE PA Article Open access 19 April 2022 A NOVEL PIPERAZINE DERIVATIVE THAT TARGETS HEPATITIS B SURFACE ANTIGEN

EFFECTIVELY INHIBITS TENOFOVIR RESISTANT HEPATITIS B VIRUS Article Open access 03 June 2021 REFERENCES * Yang HI, Lu SN, Liaw YF, You SL, Sun CA, Wang LY, Hsiao CK, Chen PJ, Chen DS, Chen

CJ, Taiwan Community-Based Cancer Screening Project Group 2002. Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Eng J Med. 2002;347:168–74. Article  CAS  Google Scholar  *

Durantel D, Zoulim F. New antiviral targets for innovative treatment concepts for hepatitis B virus and hepatitis delta virus. J Hepatol. 2016;64:S117–31. Article  CAS  PubMed  Google

Scholar  * Pei Y, Wang C, Yan SF, Liu G. Past, current, and future developments of therapeutic agents for treatment of chronic hepatitis B virus infection. J Med Chem. 2017;60:6461–79.

Article  CAS  PubMed  Google Scholar  * Beck J, Nassal M. Hepatitis B virus replication. World J Gastroenterol. 2007;13:48–64. Article  CAS  PubMed  PubMed Central  Google Scholar  * Seeger

C, Mason WS. Molecular biology of hepatitis B virus infection. Virology. 2015;479-480:672–86. Article  CAS  PubMed  Google Scholar  * Suzuki M, Kondo S, Yamasaki M, Matsuda N, Nomoto A,

Suzuki T, Saito I, Kanegae Y. Efficient genome replication of hepatitis B virus using adenovirus vector: a compact pregenomic RNA-expression unit. Sci Rep. 2017;7:41851. Article  CAS  PubMed

  PubMed Central  Google Scholar  * Takizawa N, Yamasaki M. Current landscape and future prospects of antiviral drugs derived from microbial products. J Antibiot. 2017;71:45–52. Article 

Google Scholar  * Yamasaki M, Matsuda N, Matoba K, Kondo S, Kanegae Y, Saito I, Nomoto A. Acetophenone 4-nitrophenylhydrazone inhibits Hepatitis B virus replication by modulating capsid

assembly. Virus Res. 2021;306:198565. Article  CAS  PubMed  Google Scholar  * Nishio M, Tomatsu K, Konishi M, Tomita K, Oki T, Kawaguchi H, Clardy J. Karnamicin, a complex of new antifungal

antibiotics. I. Taxonomy, fermentation, isolation and physico-chemical and biological properties. J Antibiot. 1989;42:852–68. Article  CAS  Google Scholar  * Urban M, McMillan DJ, Canning G,

Newell A, Brown E, Mills JS, Jupp R. In vitro activity of hepatitis B virus polymerase: requirement for distinct metal ions and the viral epsilon stem-loop. J Gen Virol. 1998;79:1121–31.

Article  CAS  PubMed  Google Scholar  * Toyoda T, Wang Y, Wen Y, Tanaka Y. Fluorescence-based biochemical analysis of human hepatitis B virus reverse transcriptase activity. Anal Biochem.

2020;597:113642. Article  CAS  PubMed  Google Scholar  * Chang LJ, Hirsch RC, Ganem D, Varmus HE. Effects of insertional and point mutations on the functions of the duck hepatitis B virus

polymerase. J Virol. 1990;64:5553–8. Article  CAS  PubMed  PubMed Central  Google Scholar  * Wei X, Peterson DL. Expression, purification, and characterization of an active RNase H domain of

the hepatitis B viral polymerase. J Biol Chem. 1996;271:32617–22. Article  CAS  PubMed  Google Scholar  * Lu G, Lomonosova E, Cheng X, Moran EA, Meyers MJ, Le Grice SF, Thomas CJ, Jiang JK,

Meck C, Hirsch DR, D’Erasmo MP, Suyabatmaz DM, Murelli RP, Tavis JE. Hydroxylated tropolones inhibit hepatitis B virus replication by blocking viral ribonuclease H activity. Antimicrob

Agents Chemother. 2015;59:1070–9. Article  PubMed  PubMed Central  Google Scholar  * Jiang B, Hildt E. Intracellular trafficking of HBV particles. Cells. 2020;9:2023. Article  CAS  PubMed 

PubMed Central  Google Scholar  * Lenhoff RJ, Summers J. Coordinate regulation of replication and virus assembly by the large envelope protein of an avian hepadnavirus. J Virol.

1994;68:4565–71. Article  CAS  PubMed  PubMed Central  Google Scholar  * Ning X, Nguyen D, Mentzer L, Adams C, Lee H, Ashley R, Hafenstein S, Hu J. Secretion of genome-free hepatitis B virus

- single strand blocking model for virion morphogenesis of para-retrovirus. PLoS Pathog. 2011;7:e1002255. Article  CAS  PubMed  PubMed Central  Google Scholar  * Bai L, Zhang X, Kozlowski

M, Li W, Wu M, Liu J, Chen L, Zhang J, Huang Y, Yuan Z. Extracellular hepatitis B Virus RNAs are heterogeneous in length and circulate as capsid-antibody complexes in addition to virions in

chronic hepatitis B patients. J Virol. 2018;92:e00798–18. Article  CAS  PubMed  PubMed Central  Google Scholar  * Yu Z, Huang JP, Yang J, Liu C, Yan Y, Wang L, Zhao J, Chen Y, Xiang W, Huang

SX. Discovery and biosynthesis of karnamicins as angiotensin converting enzyme inhibitors. Nat Commun. 2023;14:209. Article  CAS  PubMed  PubMed Central  Google Scholar  * Tsurumi Y, Ueda

H, Hayashi K, Takase S, Nishikawa M, Kiyoto S, Okuhara M. WS75624 A and B, new endothelin converting enzyme inhibitors isolated from _Saccharothrix_ sp. No. 75624. I. Taxonomy, fermentation,

isolation, physico-chemical properties and biological activities. J Antibiot. 1995;48:1066–72. Article  CAS  Google Scholar  * Yoshimura S, Tsurumi Y, Takase S, Okuhara M. WS75624 A and B,

new endothelin converting enzyme inhibitors isolated from _Saccharothrix_ sp. No. 75624. II. Structure elucidation of WS75624 A and B. J Antibiot. 1995;48:1073–5. Article  CAS  Google

Scholar  * Kimura T, Inahashi Y, Matsuo H, Suga T, Iwatsuki M, Shiomi K, Takahashi Y, Ōmura S, Nakashima T. Pyrizomicin A and B: structure and bioactivity of new thiazolyl pyridines from

_Lechevalieria aerocolonigenes_ K10-0216. J Antibiot. 2018;71:606–8. Article  CAS  Google Scholar  * Guo F, Zhao Q, Sheraz M, Cheng J, Qi Y, Su Q, Cuconati A, Wei L, Du Y, Li W, Chang J, Guo

JT. HBV core protein allosteric modulators differentially alter cccDNA biosynthesis from de novo infection and intracellular amplification pathways. PLoS Pathog. 2017;13:e1006658. Article 

PubMed  PubMed Central  Google Scholar  Download references ACKNOWLEDGEMENTS We thank Dr. Yasuhiro Takehana and Ms. Rie Arisaka for their technical assistance with isolating

catenulopyrizomicins, and Dr. Kiyoko Iijima for the HRESI-MS and NMR measurements. We would like to thank Editage (www.editage.jp) for English language editing. This study is dedicated to

the memory of Dr. Akio Nomoto, passed away in 2014, who inspired us a lot to find microbial compounds with antiviral activities. This study was supported by JSPS KAKENHI (grant number

JP15K08507) and the Research Program on Hepatitis of the Japan Agency for Medical Research and Development (AMED) (grant number JP20fk0310102). AUTHOR INFORMATION AUTHORS AND AFFILIATIONS *

Institute of Microbial Chemistry (BIKAKEN), Shinagawa-ku, Tokyo, Japan Manabu Yamasaki, Ryuichi Sawa, Hideyuki Muramatsu, Yui Yamamoto, Maya Umekita, Yumiko Kubota & Masayuki Igarashi *

Core Research Facilities of Basic Science, Research Center for Medical Science, The Jikei University School of Medicine, Minato-ku, Tokyo, Japan Yumi Kanegae Authors * Manabu Yamasaki View

author publications You can also search for this author inPubMed Google Scholar * Ryuichi Sawa View author publications You can also search for this author inPubMed Google Scholar * Hideyuki

Muramatsu View author publications You can also search for this author inPubMed Google Scholar * Yui Yamamoto View author publications You can also search for this author inPubMed Google

Scholar * Maya Umekita View author publications You can also search for this author inPubMed Google Scholar * Yumiko Kubota View author publications You can also search for this author

inPubMed Google Scholar * Yumi Kanegae View author publications You can also search for this author inPubMed Google Scholar * Masayuki Igarashi View author publications You can also search

for this author inPubMed Google Scholar CORRESPONDING AUTHOR Correspondence to Manabu Yamasaki. ETHICS DECLARATIONS CONFLICT OF INTEREST The authors declare no competing interests.

ADDITIONAL INFORMATION PUBLISHER’S NOTE Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. SUPPLEMENTARY INFORMATION

SUPPLEMENTARY INFORMATION RIGHTS AND PERMISSIONS Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with

the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable

law. Reprints and permissions ABOUT THIS ARTICLE CITE THIS ARTICLE Yamasaki, M., Sawa, R., Muramatsu, H. _et al._ Catenulopyrizomicins, new anti-Hepatitis B virus compounds, from the rare

actinomycete _Catenuloplanes_ sp. MM782L-181F7. _J Antibiot_ 77, 85–92 (2024). https://doi.org/10.1038/s41429-023-00681-4 Download citation * Received: 25 September 2023 * Revised: 31

October 2023 * Accepted: 01 November 2023 * Published: 27 November 2023 * Issue Date: February 2024 * DOI: https://doi.org/10.1038/s41429-023-00681-4 SHARE THIS ARTICLE Anyone you share the

following link with will be able to read this content: Get shareable link Sorry, a shareable link is not currently available for this article. Copy to clipboard Provided by the Springer

Nature SharedIt content-sharing initiative